Sight Sciences, Inc.
SGHT Healthcare Medical Devices
Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024. In the quarter to June 2026, revenue grew 19.6%, EPS grew 65.2%, free cash flow grew 26.7% and total debt rose 2.40%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SGHT
Sight Sciences, Inc. (SGHT) Altman Z-score
Sight Sciences, Inc.'s Altman Z-score for fiscal 2025 is 0.83, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 0.83 | 1.81 |
| FY2024 | −0.98 | (2.18) |
| FY2023 | 1.20 | (3.95) |
| FY2022 | 5.16 | (0.64) |
| FY2021 | 5.79 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.88 | — | 1.06 | |
| Retained earnings / total assets | (3.34) | — | −4.67 | |
| EBIT / total assets | (0.32) | — | −1.06 | |
| Market value of equity / total liabilities | 8.05 | — | 4.83 | |
| Sales / total assets | 0.67 | — | 0.67 | |
| Altman Z-score | Distress zone | 0.83 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −5.95 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| SSII SS Innovations International, Inc. compare | 17.5× |
| DCTH Delcath Systems, Inc. compare | 13.3× |
| TCMD Tactile Systems Technology, Inc. compare | 9.6× |
| BWAY Brainsway Ltd. Sponsored ADR compare | 2.8× |
| MASS 908 Devices Inc. compare | 1.1× |
| SGHT Sight Sciences, Inc. | 0.8× |
| NPCE NeuroPace, Inc. compare | −2.5× |
| CERS Cerus Corporation compare | −4.0× |
| SENS Senseonics Holdings, Inc. compare | −9.8× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets